Description
Testosterone Propionate is the shortest of the common test esters, formed by esterification at the 17β-hydroxyl with propionic acid. The three-carbon side chain makes the compound less lipophilic and therefore faster-releasing from the oily injection depot than Enanthate or Cypionate.
Per study reports the elimination half-life is only about 0.8 days (roughly 19 hours). Studies administer Propionate every 1-2 days, otherwise the plasma level profile fluctuates too widely. After ester cleavage, free testosterone acts via the androgen receptor as with all esters.
The rapid on-off profile has two important use cases in research: first, for short cycles or protocol phases where fast rise and fall are desired. Second, for pre-contest studies (competitive bodybuilding research), because test values normalize faster after discontinuation than with long-acting esters.
The higher injection frequency means more daily-life burden and more injection-site stress in research practice. Post-injection inflammation (PIP) incidence is documented as higher with Propionate than with long esters - presumably due to higher esterase turnover at the depot site.
You can order Testosterone Propionate as an oily injection solution in 10-vial packs at 100mg/ml or 200mg/ml.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Testosterone Propionate shares the risk profile of all testosterone esters - the effects described in the literature are well documented. The short half-life allows only faster clearance, not a milder profile.
Documented in studies and the application literature:
- Estrogen conversion: testosterone aromatizes to estradiol. Water retention, blood pressure rise and at higher doses gynecomastia risk are documented.
- Suppression of endogenous production: exogenous testosterone throttles the body’s own production via the HPTA axis. Testicular atrophy and reduced fertility are documented, recovery after discontinuation is not guaranteed.
- Cardiovascular: studies describe unfavorable shifts in the lipid profile (HDL falls), elevated hematocrit and an associated thrombosis risk.
- Other: acne, accelerated hair loss with genetic predisposition, mood swings. The every-1-2-days injections increase strain on the injection sites, a higher post-injection inflammation is documented.
Baseline bloodwork before, during and after a research protocol is strongly advised. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Pharmacokinetic Properties of Testosterone Propionate in Normal Men - The Journal of Clinical Endocrinology and Metabolism 1986, Fujioka et al: Tracks the plasma profile after intramuscular Propionate administration - levels stay above the physiologic range for about 48 hours, followed by rapid clearance.
- Influence of solvent on the availability of testosterone propionate from oily, intramuscular injections in the rat - Journal of Pharmacy and Pharmacology 1987, Al-Hindawi et al: Preclinical study showing how the oil vehicle governs the release rate of Propionate from the injection depot.
- The Effects of Supraphysiologic Doses of Testosterone on Muscle Size and Strength in Normal Men - New England Journal of Medicine 1996, Bhasin et al: Dose-response study on testosterone in supraphysiologic doses.
- Comparative pharmacokinetics of testosterone esters - Testosterone (Springer) 1998, Behre & Nieschlag: Compares the pharmacokinetics of the common test esters from Propionate through Undecanoate.
- Pharmacology of testosterone replacement therapy preparations - Translational Andrology and Urology 2016, Shoskes et al: Pharmacokinetics and adverse-effect profile of the common esters including Propionate.
